251 related articles for article (PubMed ID: 32359398)
1. Identification of a Structural Determinant for Selective Targeting of HDMX.
Ben-Nun Y; Seo HS; Harvey EP; Hauseman ZJ; Wales TE; Newman CE; Cathcart AM; Engen JR; Dhe-Paganon S; Walensky LD
Structure; 2020 Jul; 28(7):847-857.e5. PubMed ID: 32359398
[TBL] [Abstract][Full Text] [Related]
2. A stapled p53 helix overcomes HDMX-mediated suppression of p53.
Bernal F; Wade M; Godes M; Davis TN; Whitehead DG; Kung AL; Wahl GM; Walensky LD
Cancer Cell; 2010 Nov; 18(5):411-22. PubMed ID: 21075307
[TBL] [Abstract][Full Text] [Related]
3. Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes.
Kallen J; Izaac A; Chau S; Wirth E; Schoepfer J; Mah R; Schlapbach A; Stutz S; Vaupel A; Guagnano V; Masuya K; Stachyra TM; Salem B; Chene P; Gessier F; Holzer P; Furet P
ChemMedChem; 2019 Jul; 14(14):1305-1314. PubMed ID: 31066983
[TBL] [Abstract][Full Text] [Related]
4. Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes.
Kallen J; Goepfert A; Blechschmidt A; Izaac A; Geiser M; Tavares G; Ramage P; Furet P; Masuya K; Lisztwan J
J Biol Chem; 2009 Mar; 284(13):8812-21. PubMed ID: 19153082
[TBL] [Abstract][Full Text] [Related]
5. Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system.
Datta S; Bucks ME; Koley D; Lim PX; Savinov SN
Bioorg Med Chem; 2010 Aug; 18(16):6099-108. PubMed ID: 20638853
[TBL] [Abstract][Full Text] [Related]
6. N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.
Hayashi R; Wang D; Hara T; Iera JA; Durell SR; Appella DH
Bioorg Med Chem; 2009 Dec; 17(23):7884-93. PubMed ID: 19880322
[TBL] [Abstract][Full Text] [Related]
7. HDM2 and HDMX Proteins in Human Cancer.
Hároníková L; Vojtěšek B
Klin Onkol; 2018; 31(Suppl 2):63-70. PubMed ID: 31023026
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting.
Wachter F; Morgan AM; Godes M; Mourtada R; Bird GH; Walensky LD
Oncogene; 2017 Apr; 36(15):2184-2190. PubMed ID: 27721413
[TBL] [Abstract][Full Text] [Related]
9. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
Heminger K; Markey M; Mpagi M; Berberich SJ
Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
[TBL] [Abstract][Full Text] [Related]
10. p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction.
Medina-Medina I; Martínez-Sánchez M; Hernández-Monge J; Fahraeus R; Muller P; Olivares-Illana V
Protein Sci; 2018 May; 27(5):976-986. PubMed ID: 29524278
[TBL] [Abstract][Full Text] [Related]
11. Understanding the interaction of 14-3-3 proteins with hDMX and hDM2: a structural and biophysical study.
Srdanović S; Wolter M; Trinh CH; Ottmann C; Warriner SL; Wilson AJ
FEBS J; 2022 Sep; 289(17):5341-5358. PubMed ID: 35286747
[TBL] [Abstract][Full Text] [Related]
12. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.
Spinnler C; Hedström E; Li H; de Lange J; Nikulenkov F; Teunisse AF; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
Cell Death Differ; 2011 Nov; 18(11):1736-45. PubMed ID: 21546907
[TBL] [Abstract][Full Text] [Related]
13. c-Abl phosphorylates Hdmx and regulates its interaction with p53.
Zuckerman V; Lenos K; Popowicz GM; Silberman I; Grossman T; Marine JC; Holak TA; Jochemsen AG; Haupt Y
J Biol Chem; 2009 Feb; 284(6):4031-9. PubMed ID: 19075013
[TBL] [Abstract][Full Text] [Related]
14. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
[TBL] [Abstract][Full Text] [Related]
15. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
[TBL] [Abstract][Full Text] [Related]
16. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.
Linares LK; Hengstermann A; Ciechanover A; Müller S; Scheffner M
Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12009-14. PubMed ID: 14507994
[TBL] [Abstract][Full Text] [Related]
17. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide.
Ji Y; Majumder S; Millard M; Borra R; Bi T; Elnagar AY; Neamati N; Shekhtman A; Camarero JA
J Am Chem Soc; 2013 Aug; 135(31):11623-11633. PubMed ID: 23848581
[TBL] [Abstract][Full Text] [Related]
18. Beta-peptides with improved affinity for hDM2 and hDMX.
Harker EA; Daniels DS; Guarracino DA; Schepartz A
Bioorg Med Chem; 2009 Mar; 17(5):2038-46. PubMed ID: 19211253
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.
Karan G; Wang H; Chakrabarti A; Karan S; Liu Z; Xia Z; Gundluru M; Moreton S; Saunthararajah Y; Jackson MW; Agarwal MK; Wald DN
Mol Cancer Ther; 2016 Apr; 15(4):574-582. PubMed ID: 26883273
[TBL] [Abstract][Full Text] [Related]
20. HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.
Phillips A; Teunisse A; Lam S; Lodder K; Darley M; Emaduddin M; Wolf A; Richter J; de Lange J; Verlaan-de Vries M; Lenos K; Böhnke A; Bartel F; Blaydes JP; Jochemsen AG
J Biol Chem; 2010 Sep; 285(38):29111-27. PubMed ID: 20659896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
